C4 Therapeutics, Inc. (CCCC) Form 8-K — Aug 11, 2026
C4 Therapeutics reported second quarter 2026 revenue of $6.6 million and a net loss of $23.6 million, or $0.18 per share, compared with a $26.0 million net loss, or $0.37 per share, in the year-ago quarter, as R&D and G&A expenses both declined year over year. Cash, cash equivalents and marketable securities stood at $300.4 million as of June 30, 2026, lifted by $33.5 million in net ATM proceeds and a $20 million upfront payment from a new April 2026 Roche collaboration on degrader-antibody conjugates; management expects this cash to fund operations through the end of 2028.
Key figures
- Revenue
- $6.6 million
- Guidance
- Cash, cash equivalents and marketable securities expected to fund operations to the end of 2028
- Net Income
- -$23.6 million (net loss); -$26.0 million in Q2 2025
- Revenue Yoy
- up from $6.5 million in Q2 2025
- Total Assets
- $359.4 million
- Cash Position
- $300.4 million
- Cash march 31 2026
- $268.3 million
- G a expense q2 2026
- $8.6 million
- R d expense q2 2026
- $24.5 million
- Phase1 orr 75ug dose
- 40%
- Cash december 31 2025
- $297.1 million
- Phase1 orr 100ug dose
- 53%
- Six month 2026 net loss
- -$48.8 million
- Atm net proceeds q2 2026
- $33.5 million
- Roche collaboration upfront
- $20 million
- Weighted avg shares q2 2025
- 71005743
- Weighted avg shares q2 2026
- 130696742
Price after filing
Close on the filing date to close N calendar days later (from $3.73). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.